Walleye Trading
IMVT icon

Walleye Trading’s Immunovant IMVT Stock Holding History

Walleye Trading’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,390
Closed -$744K – 5033
2023
Q4 		$859K Buy
20,390
+13,420
+193% +$494K ﹤0.01% 2610
2023
Q3 		$268K Buy
+6,970
New +$158K ﹤0.01% 3432
2023
Q1 		– Sell
-28,051
Closed -$498K – 5084
2022
Q4 		$498K Buy
28,051
+14,678
+110% +$185K ﹤0.01% 2819
2022
Q3 		$75K Buy
+13,373
New +$65.4K ﹤0.01% 4148
2021
Q3 		– Sell
-11,737
Closed -$124K – 5436
2021
Q2 		$124K Sell
11,737
-12,461
-51% -$174K ﹤0.01% 4272
2021
Q1 		$388K Buy
+24,198
New +$638K ﹤0.01% 2959
2019
Q4 		– Sell
-130,727
Closed -$1.28M – 4424
2019
Q3 		$1.28M Buy
+130,727
New +$1.29M 0.01% 1407

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Walleye Trading's IMVT Position: Q1 2024 in Review

Walleye Trading sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 20,390 shares — an estimated $744K sold.

Walleye Trading first reported a position in IMVT in Q3 2019 and held it in 7 quarters. The position peaked at $1.28M in Q3 2019. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Walleye Trading reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Walleye Trading sold 20,390 Immunovant shares in Q1 2024, an estimated $744K.
  • Walleye Trading first reported a position in Immunovant in Q3 2019 and held it in 7 quarters.
  • Walleye Trading's Immunovant position peaked at $1.28M in Q3 2019.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.